Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
News|Articles|July 22, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-03-2016
- Volume 11
- Issue 8
Catalent to Commercially Supply Palatin FSD Pen Injectors
Author(s)Pharmaceutical Technology Editors
The pen injectors will be produced at Catalent’s Brussels, Belgium facility.
Advertisement
Catalent Pharma Solutions and Palatin Technologies have reached a commercial supply agreement to support the launch of Palatin’s bremelanotide pen injector product, which is used to treat female sexual dysfunction (FSD), Catalent said in a June 30, 2016 press announcement. Bremelanotide is a subcutaneous injectable peptide melanocortin receptor agonist and is designed to treat hypoactive sexual desire disorder, the most common form of FSD, in premenopausal women. The bremelanotide pen injectors will be produced at Catalent's 265,000-sq.-ft. Brussels, Belgium facility, Catalent noted. Phase III trials of bremelanotide are currently ongoing, with launch anticipated in 2018.
Source:
Articles in this issue
about 10 years ago
Slower Bio/Pharma Investment Could Hurt CDMOs in 2017about 10 years ago
Supply Chain Partner Scrutiny Moves Beyond GMPsabout 10 years ago
Chiral Advances Demonstrate Promise for API Synthesisabout 10 years ago
NIST Issues mAb Reference Standardover 10 years ago
EMA Suspends Drugs Due to Flawed Bioequivalence Studiesover 10 years ago
CordenPharma Expands into Oligonucleotide APIsover 10 years ago
Shimadzu System Combines HPLC and UHPLC Methodsover 10 years ago
Zenith Appoints Serialization Directorover 10 years ago
CSafe Opens Facility in Puerto RicoAdvertisement
Related to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
Germany’s Medical Biotechnology Sector is Flourishing
4
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
5